Stockscreener 앱 받기
4.33
0.23%
0.010
시간 외 거래:
4.33
전일 마감가:
$4.32
열려 있는:
$4.32
하루 거래량:
229.80K
Relative Volume:
2.56
시가총액:
$37.62M
수익:
$2.74M
순이익/손실:
$-41.38M
주가수익비율:
-0.9193
EPS:
-4.71
순현금흐름:
$-31.10M
1주 성능:
+0.00%
1개월 성능:
+16.08%
6개월 성능:
+71.83%
1년 성능:
+41.97%
1일 변동 폭
$4.31
$4.38
1주일 범위
$4.30
$4.39
52주 변동 폭
$1.3701
$4.5756
Lumos Pharma Inc Stock (LUMO) Company Profile
명칭
Lumos Pharma Inc
전화
512-215-2630
주소
4200 MARATHON BLVD., AUSTIN, TX
LUMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| LUMO | 4.33 | 37.62M | 2.74M | -41.38M | -31.10M | -4.71 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Lumos Pharma Inc Stock (LUMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-11 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-03 | 개시 | Cantor Fitzgerald | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-17 | 재개 | ROTH Capital | Buy |
| 2020-08-04 | 개시 | H.C. Wainwright | Buy |
Lumos Pharma Inc 주식(LUMO)의 최신 뉴스
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 - GlobeNewswire
Lumos Pharma Faces Uncertainty as CVRs Risk Expiring Worthless Post-Merger - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, OB on Behalf of Shareholders - GlobeNewswire
Private Advisor Group, LLC Acquires Shares in Lumos Pharma Inc - GuruFocus.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ALTR, STAF on Behalf of Shareholders - Marketscreener.com
Finansavisen - Finansavisen
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Reviews the Merger of STAF, ATSG, GABC and LUMO - AccessWire
$HAREHOLDER ALERT FOR STAF, ATSG, GABC and ALTM: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire
Lumos: Q3 Earnings Snapshot - CT Insider
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, INSI on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO - GlobeNewswire Inc.
Peregrine Gold Ltd Confirms Prospectus Lodgement for Security Issue - MSN
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024 - The Manila Times
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders - cnhinews.com
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Discover Smart Share Global Among 2 Other Prominent US Penny Stocks - Simply Wall St
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ZUO, ARC on Behalf of Shareholders - Stockhouse Publishing
Analyst Expectations For Lumos Pharma's Future - Benzinga
INVESTIGATION ALERT: Halper Sadeh LLC Continues to - GlobeNewswire
Kuehn Law Encourages MMLP, ICCH, FSHP, and LUMO Investors to Contact Law Firm - Morningstar
DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology
Lumos Pharma to be acquired by Double Point Ventures - Investing.com Canada
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc. - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders - Longview News-Journal
Jones Trading cuts Lumos Pharma shares rating amid Double Point merger - Investing.com UK
Lumos inks take-private deal with Double Point Ventures - MSN
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders - Business Wire
Lumos Pharma Shares Rally After Double Point Deal - MarketWatch
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - The Manila Times
Lumos stock in focus after take-private deal (LUMO:NASDAQ) - Seeking Alpha
Double Point to Buy Lumos Pharma for $38M as FDA OKs Lumos Drug Trial - MarketWatch
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, USAP, SASR on Behalf of Shareholders - cnhinews.com
Hypopituitarism Market Forecasted to Surge in Coming Years, - openPR
Lumos Pharma Inc (LUMO) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Prudence - Investing.com Canada
Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience. - Proactive Investors USA
Lumos Pharma maintains target with Buy rating by H.C. Wainwright - Investing.com Canada
Lumos Pharma (NASDAQ:LUMO) Rating Reiterated by HC Wainwright - Defense World
Clene (NASDAQ:CLNN) Stock Quotes, Forecast and News Summary - Benzinga
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024 - ForexTV.com
Apple's iPhone 16 lead times track below past three cycles: MS - Head Topics
You might want to take a look at Lumen Technologies Inc (LUMN) now - SETE News
Stocks of Lexicon Pharmaceuticals Inc (LXRX) are poised to climb above their peers - SETE News
Lumen Technologies (NYSE:LUMN) Trading Down 2.9% - MarketBeat
Caxton Associates LP Increases Stock Holdings in Lululemon Athletica Inc. (NASDAQ:LULU) - Defense World
Lufax Holding Ltd ADR [LU] Revenue clocked in at $3.82 billion, up 83.43% YTD: What’s Next? - The DBT News
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Lululemon Athletica Inc.LULU - PR Newswire
Oct. 7th Deadline Alert: Investors Who Lost More Than $100,000 With Lululemon Athletica Inc. (NASDAQ: LULU) Shares Should Contact the Shareholders Foundation - Newswire
Analytical Overview: Lumen Technologies Inc (LUMN)’s Ratios Tell a Financial Story - The Dwinnex
LB Aluminium's 1Q profit doubles as revenue hits highest in two decades - The Edge Malaysia
Lumen Technologies Inc (NYSE: LUMN) – An Analysis Is What You Need - Stocks Register
Lumos Pharma Inc (LUMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lumos Pharma Inc 주식 (LUMO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McKew John C. | Chief Scientific Officer |
Apr 03 '24 |
Sale |
2.77 |
2,214 |
6,144 |
17,153 |
| McKew John C. | Chief Scientific Officer |
Feb 06 '24 |
Sale |
3.03 |
438 |
1,328 |
18,403 |
0.93%
3.55%
자본화:
|
볼륨(24시간):